ArticleInflammopharmacology2026
Wild chrysanthemum essential oil alleviates dry eye disease by inhibiting NF-κB-mediated inflammation.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED), a disorder with multiple contributing factors, is marked by instability in the tear film, increased osmolarity, and inflammatory responses. This research investigates the therapeutic potential of essential oil derived from wild chrysanthemum essential oil (CHEO) in treating DED. GC-MS analysis identified 121 bioactive compounds in CHEO, including L-borneol (6.00%) and β-sitosterol (4.60%), compounds with established anti-inflammatory properties. In human corneal epithelial cells subjected to hyperosmotic stress, CHEO treatment significantly improved cell viability and lowered inflammatory cytokines (IL-1β, IL-6, TNF-α) secretion. CHEO administration was demonstrated to restore tear production, improve corneal epithelial integrity, and increase conjunctival goblet cell density in scopolamine-induced DED mice. Notably, the ocular tissues demonstrated suppression of mitogen-activated protein kinases (MAPK) and NF-κB pathway activation by CHEO. The collective evidence indicates that CHEO alleviates DED through multimodal mechanisms involving anti-inflammatory action and ocular surface protection, highlighting its promise as a new phytotherapeutic option for managing DED.
Indexed as
Identifiers
41615571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.